Academic Highlights: New Insights Into Genetics and Pathophysiology of Alzheimer's Disease: What Are the Clinical and Therapeutic Implications?
J Clin Psychiatry 2000;61:307-315
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Genetic findings have made an
important contribution to the understanding
of Alzheimer’s disease. The
mutations in β-amyloid precursor protein
(βAPP) and presenilin 1 (PS1)
transmitted in a simple Mendelian manner
have provided the basis for our
understanding of the central role of
β-amyloid in all cases of Alzheimer’s.
Dr. Mullan suggested that whereas
variability at the apolipoprotein E
(APOE) locus is clearly associated with
the occurrence of disease, for many
other genes such clarity is less established.